Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: Meta-analysis of six randomized controlled trials

Journal of the American Geriatrics Society

Volumn 50, Issue 12, 2002, Pages 1939-1946

  Regensteiner, Judith G ^a   Ware Jr , John E ^b   McCarthy, Walter J ^c   Zhang, Peter ^d   Forbes, William P ^d   Heckman, Jeffrey ^d   Hiatt, William R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Cilostazol; Health related quality of life; Meta analysis; Randomized controlled trial; Treadmill exercise test

Indexed keywords

CILOSTAZOL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOMES RESEARCH; PATIENT INFORMATION; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREADMILL ERGOMETRY; VALIDATION PROCESS; WALKING;

AGED; EXERCISE TEST; HUMANS; INTERMITTENT CLAUDICATION; INTRACRANIAL ARTERIAL DISEASES; MALE; MULTICENTER STUDIES; PERIPHERAL VASCULAR DISEASES; PHOSPHODIESTERASE INHIBITORS; POLYHYDROXYETHYL METHACRYLATE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES; WALKING;

EID: 18744378546     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2002.50604.x     Document Type: Article

References (21)

1. Beebe HG, Dawson DL, Cutler BS et al. A new pharmacological treatment for intermittent claudication. Results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-2049.
2. Elam MB, Heckman J, Crouse JR et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998;18:1942-1947.
3. Money SR, Herd JA, Isaacsohn JL et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-274.
4. Strandness DE Jr. Two doses of cilostazol versus placebo in the treatment of claudication: Results of a randomized, multicenter trial [abstract 59]. Circulation 1998;95:1-12.
5. Data on File. Otsuka America Pharmaceutical, Inc.
6. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109: 523-530.
7. Regensteiner JG, Steiner JF, Panzer RJ et al. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol 1990;2:142-152.
8. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996;23:104-115.
9. McDermott MM, Liu K, Guralnik JM et al. Measurement of walking endurance and walking velocity with questionnaire: Validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg 1998;28:1072-1081.
10. Tarlov AR, Ware JE Jr, Greenfield S et al. The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA 1989;262:925-930.
11. Hiatt WR, Nawaz D, Regensteiner JG et al. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulm Rehabil 1988;12:525-532.
12. Gardner AW, Skinner JS, Cantwell BW et al. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc 1991;23:402-408.
13. Gardner AW, Womack CJ, Montgomery PS et al. Cigarette smoking shortens the duration of daily leisure time physical activity in patients with intermittent claudication. J Cardiopulm Rehabil 1999;19:43-51.
14. Feinglass J, McCarthy WJ, Slavensky R et al. Functional status and walking ability after lower extremity bypass grafting or angioplasty for intermittent claudication: Results from a prospective outcomes study. J Vasc Surg 2000; 31:93-103.
15. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31: 247-263.
16. Ware JE Jr, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Assessment Lab, New England Medical Center, 1994.
17. Ware JE Jr, Kosinski M, Bayliss MS et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: Summary of results from the Medical Outcomes Study. Med Care 1995;33:AS264-AS279.
18. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, CA: Academic Press, Inc., 1985.
19. Hiatt WR, Regensteiner JG, Hargarten ME et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990;81:602-609.
20. Ware JE, Kosinski M. SF-36 Physical and Mental Health Summary Scales: A Manual for Users of Version 1, 2nd Ed. Lincoln, RI: QualityMetric, Inc., 2001.
21. Samsa G, Edelman D, Rothman ML et al. Determining clinically important differences in health status measures. A general approach with illustration of the Health Utilities Index Mark II. Pharmacoeconomics 1999;5:141-155.